Related to Cisbio to Distribute Multispan’s Portfolio of GPCR Cell Lines in the U.S.

• BioTime and XenneX Establish LifeMap to Generate Database of Stem Cell Lineages
  
• Takeda and Heptares Ink Drug Discovery Deal for CNS Diseases
  
• Horizon and Fox Chase Establish Gene-Editing Collaboration and Center of Excellence
  
• Shire Negotiates Option to Heptares Preclinical-Stage A2A Antagonist Program
  
• Goodwin Biotechnology and Rafagen Ink Deal for Biomanufacturing and Cell-Line Development
  
• AstraZeneca Pays Heptares $6.25M to Tap GPCR Expertise for Therapeutic Development
  
• Cevec and Catalent Ally to Offer Cell-Line Development Service
  
• Scientists Report on Publicly Available Mouse Embryonic Stem Cell miRNA Knockout Resource
  
• Horizon Raises $18.6M in Series C Financing to Broaden Utility of X-Man Platform
  
• Inhibrx Taps ProBioGen to Boost ADCC Potency of Antibody Candidates
  
• EMD Millipore to Distribute Biopredic’s HepaRG Human Hepatic Cells
  
• Horizon and Promega Ally on Cancer Models for Development of Targeted Drug Therapies
  
• NCI/NHGRI Taps Horizon's Gene-Editing Platform
  
• CompuGen, DiscoveRx to Develop Peptides Against GPCRs
  
• Ono, Receptos Ink GPCR Drug Discovery Collaboration
  
• Dana-Farber Licenses Luciferase-Reporter Cancer Cell Lines to Molecular Imaging
  
• BioTime Gains Option to Use USCN Cell Lines in Cancer Dx Development
  
• Horizon, RFUMS to Generate Human Cell Cystic Fibrosis Model
  
• Cancer Cell Line Encyclopedia Released to Aid Drug Discovery and Clinical Trials
  
• Lonza to Carry Out Process Development for Immutep’s Lead Cancer Immunotherapy